Ovarian Cancer
Conditions
Keywords
ovarian cancer, tyrosine kinase inhibitor
Brief summary
The objective is to evaluate the efficacy and safety of masitinib in combination with gemcitabine in refractory ovarian cancer patients.
Detailed description
Masitinib is a selective tyrosine kinase inhibitor that is thought to promote survival via modulation of immunostimulation-mediated anticancer effects and modulation of the tumor microenvironment. The objective of this study is to evaluate the efficacy and safety of masitinib in combination with gemcitabine as compared with single agent gemcitabine in advanced or metastatic epithelial ovarian cancer patients who are refractory to platinum treatment. This is an open-label, randomized, active-controlled, phase 2/3 study. The study's primary efficacy measure will be overall survival. Masitinib will be prescribed until disease progression (or treatment switch to next line of treatment), death, limiting toxicity or patient consent withdrawal. The study design is a two-stage adaptive design, meaning that it includes a prospectively planned opportunity for modification of one or more specified aspects of the study (for example patient enrollment).
Interventions
DRUGMasitinib
DRUGGemcitabine
DRUGPlacebo
Sponsors
AB Science
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Main inclusion criteria: 1. Female patient, with histologically or cytologically confirmed advanced / metastatic epithelial ovarian cancer (including primary peritoneal and primary fallopian tube cancer), which is either: * First line platinum-refractory ovarian cancer (progression during first-line platinum-based chemotherapy) * First line platinum-resistant ovarian cancer (relapsing within 6 months after the end of first-line chemotherapy); * Candidate to third line of treatment (refractory, resistant, or sensitive to 2nd line platinum-based therapy or patients who progressed after other type of chemotherapy in 2nd line). 2. Patient with adequate organ function per laboratory tests evaluations Main
Exclusion criteria
1. Patient intolerant to gemcitabine 2. Patient who has not recovered from any significant treatment toxicities prior to baseline (≥Grade 2) 3. Pregnant or nursing female patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | From day of randomization to death, assessed for a maximum of 60 months | Overall survival is defined as time in months from the randomization date to the date of death due to any cause. If a patient is not known to have died, then OS will be censored at the date of last known date patient alive. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Progression Free Survival (PFS) | From day of randomization to disease progression or death, assessed for a maximum of 60 months | Progression Free Survival (PFS) \[Time Frame: From day of randomization to disease progression or death, assessed for a maximum of 60 months\] Progression Free Survival is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Disease progression will be assessed by CT scan according to RECIST criteria recommendations. |
Countries
Algeria, France, Russia, Spain, Ukraine, United Kingdom
Outcome results
None listed